Advertisement

Hormonal effects of the 300 μg norethisterone (NET) minipill

1. Daily steroid levels in 43 subjects during a pretreatment cycle alnd during the second month of NET administration
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The ovarian effects of the 300 μg norethisterone (NET) minipill were investigated in 43 normally menstruating women by the daily analysis of the peripheral plasma levels of estradiol and progester-one in a pretreatment (control) cycle and during the second month of NET administration. During the latter period, the daily levels of NET were also measured. The assessment of normal values characterizing an ovulatory cycle was based on the results of a previous study, indicating Math Eq that in a normal luteal phase, 95 out of 100 normally menstruating women of the local study population exhibit plasma progesterone levels exceeding 16 nmol/1 for a minimum of five days.
      The present study revealed four characteristic and distinctly different types of ovarian reaction to the NET minipill; seven subjects (16%) exhibited no signs of follicular or luteal activity as evidenced by the low estradiol and progesterone levels (Math Eq), ten subjects (23%) showed a marked cyclic follicular activity, but no luteal function (group B), nine subjects (21%) had a normal follicular activity, but a significantly reduced (insufficient) luteal activity (Math Eq),and 17 subjects (40%) exhibited estradiol and progesterone profiles which were indistinguishable from those found in normally menstruating women, in general, and in their pretreatment cycles, in particular (Math Eq).
      Compared to the characteristics of the pretreatment cycles, the administration of NET resulted in a shortening of the luteal phase in group C and in a lengthening of the follicular phase together with a shortening of the luteal phase in group D.
      The plasma levels of NET closely reflected the regularity (or irregularity) of pill taking by the various subjects and the time interval elapsing between pill taking and blood withdrawal. There was no correlation between the levels of NET and the types of ovarian reaction induced, or of the bleeding profile.
      Compared to the bleeding profile of the pretreatment period, the administration of NET increased the number of episodes and the number of days with bleeding and spotting and reduced the average bleeding-free interval. In this limited study, no difference could be established in the bleeding patterns observed in the various groups.
      An important aspect of this investigation was to assess whether or not the ovarian reaction to the NET minipill can be predicted from the analysis of previous reproductive events and/or the hormonal profile of the pretreatment cycle. There was a significant excess of nulliparous women in group A. Compared to the women of the three other groups, they exhibited, in their pretreatment cycle, a diminished progesterone maximum together with a prolonged follicular phase and shortened luteal phase. On the other hand, the 17 women of group D showed a shorter follicular phase and longer luteal phase than the 26 women in groups A+B+C.
      It is concluded that the relative length of follicular and luteal phases has a predictive value for the expected ovarian reaction to the NET minipill. Hence, the efficacy of the minipill might be increased by judicious selection of women exhibiting, during the pretreatment period, a high follicular to luteal phase (Math Eq) ratio (measured, for instance, by basal body temperature, or some other simple method).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Martinez-Manautou J.
        • Cortez V.
        • Giner J.
        • Aznar R.
        • Casasola J.
        • Rudel H.W.
        Low doses of progestogen as an approach to fertility control.
        Fertil. Steril. 1966; 17: 49-57
        • Martinez-Manautou J.
        • Giner-Velasquez J.
        • Cortes-Gallegos V.
        • Aznar R.
        • Rojas B.
        • Gutierrez-Najar A.
        • Rudel H.W.
        Daily progestogen for contraception.
        Brit. Med. J. 1967; 2: 730-735
        • Rinehart W.
        Minipill — A limited alternative for certain women.
        Population Reports Series A. 1975; : 54-67
        • Moghissi K.S.
        Moghissi K.S. Evans T.N. Regulation of Human Fertility. Microdose progestogens for contraception. Wayne State U.Press, Det., Mich1976: 57-84
        • Fotherby K.
        Diczfalusy E. Regulation of Human Fertility, Low doses of gestagens as fertility regulating agents. WHO Symposium, Moscow 1976 Scriptor, Copenhagen1977: 283-321
        • Østergaard E.
        • Starup J.
        Occurrence and function of corpora lutea during different forms of oral contraception.
        Acta Endocr., Kbh. 1968; 57: 386-399
        • Fotherby K.
        • Svendsen E.K.
        • Foss G.L.
        Ovarian function in women receiving low doses of a synthetic progestin, norgestrel.
        J.Reprod.Fertil. 1968; : 155-166
        • Diczfalusy E.
        • Goebelsmann U.
        • Johannisson E.
        • Tillinger K.-G.
        • Wide L.
        Pituitary and ovarian function in women on continuous low dose progestogens; effect of chlormadinone acetate and nor-ethisterone.
        Acta Endocr., Kbh. 1969; 62: 679-693
        • Larsson-Cohn U.
        • Johansson E.D.B.
        • Wide L.
        • Gemzell C.
        Effects of continuous daily administration of 0.5 mg of norethindrone on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone, pregnanediol and total oestrogens.
        Acta Endocr., Kbh. 1970; 63: 216-224
        • Larsson-Cohn U.
        • Johansson E.D.B.
        • Wide L.
        • Gemzell C.
        Effects of continuous daily administration of 0.5 mg of chlormadinone acetate on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens.
        Acta Endocr., Kbh. 1970; 63: 705-716
        • Geller S.
        • Scholler R.
        La fonction lutéale au cours des tratements par la chlormadinone a faible doses.
        Path.Biol. 1971; 19: 157-165
        • Saunders D.M.
        • Marcus S.L.
        • Saxena B.B.
        • Beling C.G.
        • Connell E.B.
        Effect of daily administration of 0.5 mg of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone and progesterone during the menstrual cycle.
        Fertil.Steril. 1971; 22: 332-344
        • Moghissi K.S.
        • Marks C.
        Effects of microdose norgestrel on endogenous gonadotropic and steroid hormones, cervical mucus properties, vaginal cytology, and endometrium.
        Fertil.Steril. 1971; 22: 424-434
        • Collins W.P.
        • Koullapis E.N.
        • Sommerville I.F.
        The effect of chlormadinone acetate on progesterone secretion and metabolism.
        Acta Endocr., Kbh. 1971; 68: 271-284
        • Moghissi K.S.
        Morphologic changes in the ovaries of women treated with continuous microdose progestógens.
        Fertil.Steril. 1972; 23: 739-744
        • Kesserü E.
        • Larranaga A.
        • Hurtado H.
        • Benavides G.
        Fertility control by continuous administration of Math Eq-norgestrel, 0.03 mg.
        Int.J.Fertil. 1972; 17: 17-27
        • Mall-Haefeli M.
        • Ludwig K.S.
        • Uettwiller A.
        The mechanism of low dose progestogen therapy.
        Clinical Trials Journal. 1974; 2: 93-109
        • Moghissi K.S.
        • Syner F.N.
        Studies on the mechanism of action of continuous microdose quingestanol acetate.
        Fertil.Steril. 1975; 26: 818-827
        • Wiese J.
        Ovarian function during treatment with lynoestrenol 0.5 mg daily.
        Acta Endocr., Kbh. 1975; 78: 325-331
        • Friedrich E.
        • Keller E.
        • Jaeger-Whitegiver E.R.
        • Joel E.W.
        • Schindler A.E.
        Effects of 0.5 mg of lynestrenol daily on hypothalamic-pituitary-ovarian function.
        Amer.J.Obstet.Gynec. 1975; 122: 642-649
        • Elstein M.
        The effect of daily norethisterone (0.35 mg) on cervical mucus and on urinary LH, pregnanediol and oestrogen levels.
        Brit.J.Obstet.Gynaec. 1976; 83: 165-168
        • Aref I.
        • Hefnawi F.
        • Kandil O.
        • Abdel Aziz M.T.
        Effect of minipills on physiologic responses of human cervical mucus, endometrium and ovary.
        Fertil.Steril. 1973; 24: 578-583
        • Gutierrez-Najar A.
        • Márquez-Monter H.
        • Cortes-Gallegos V.
        • Giner-Velasquez J.
        • Martinez-Manautou J.
        Presence of corpus luteum as evidence of ovulation in women treated with low doses of chlormadinone acetate.
        Amer.J.Obstet.Gynec. 1968; 102: 1018-1022
        • Moghissi K.S.
        • Syner F.N.
        • McBride L.C.
        Contraceptive mechanism of microdose norethindrone.
        Obstet.and Gynec. 1973; 41: 585-594
        • Diczfalusy E.
        • Landgren B.-M.
        Diczfalusy E. Regulation of Human Fertility. Hormonal changes in the menstrual cycle. WHO Symposium, Moscow 1976 Scriptor, Copenhagen1977: 21-71
      1. Landgren, B.-M., Undén, A.-L. and Diczfalusy, E.: Hormonal profile in the cycle in 68 normally menstruating women. Acta Endocr., Kbh., in press.

        • Treloar A.E.
        • Baynton R.E.
        • Behn B.G.
        • Brown B.W.
        Variation in the human menstrual cycle through reproductive life.
        Int.J.Fertil. 1967; 12: 77-126
        • Khosla T.
        • Lowe C.R.
        Indices of obesity derived from body weight and height.
        Brit.J.prev.soc.Med. 1967; 21: 122-128
        • Aso T.
        • Guerrero R.
        • Cekan Z.
        • Diczfalusy E.
        A rapid 5-hour radioimmunoassay of progesterone and oestradiol in human plasma.
        Clinical Endocrinology. 1975; 4: 173-182
        • Bedolla-Tovar N.
        • Rahman S.A.
        • Cekan S.Z.
        • Diczfalusy E.
        Assessment of the specificity of norethisterone radioimmunoassays.
        The Journal of Steroid Biochemistry. 1978; 9: 561-567
        • Gaddum J.H.
        Lognormal distribution.
        Nature (Lond.). 1945; 156: 463-466
        • Mann H.B.
        • Whitney D.R.
        On a test whether one of two random variables is stochastically larger than the other.
        Ann.Math.Statist. 1947; 18: 50-58
        • Guerrero R.
        • Aso T.
        • Brenner P.
        • Cekan Z.
        • Landgren B.-M.
        • Hagenfeldt K.
        • Diczfalusy E.
        Studies on the pattern of circulating steroids in the normal menstrual cycle. 1. Simultaneous assays of progesterone, pregnenolone, dehydroepiandrosterone, testosterone, dihydrotestosterone, androstenedione, oestradiol and oestrone.
        Acta Endocr., Kbh. 1976; 81: 133-149
        • Aedo A.-R.
        • Landgren B.-M.
        • Cekan Z.
        • Diczfalusy E.
        Studies on the pattern of circulating steroids in the normal menstrual cycle. 2. Levels of 20α-dihydroprogesterone, 17-hydroxyprogesterone and 17-hydroxypregnenolone and the assessment of their value for ovulation prediction.
        Acta Endocr., Kbh. 1976; 82: 600-616
        • Wright S.W.
        • Fotherby K.
        • Fairweather F.
        Effect of daily small doses of norgestrel on ovarian function.
        J.Obstet.Gynaec.Brit.Cwlth. 1970; 77: 65-68
        • Aref I.
        • Hefnawi F.
        • Kandil O.
        Changes in human ovaries after long-term administration of microdose progestogens.
        Contraception. 1973; 7: 503-513
        • Mukherjee T.K.
        • Wright S.W.
        • Davidson N.J.H.
        • Fotherby K.
        Effect of norgestrel on corpus luteum function.
        J.Obstet.Gynaec.Brit.Cwlth. 1972; 79: 175-182
      2. Larsson-Cohn, U.: Contraceptive treatment with low doses of gestagens. Clinical experience with daily oral administration of 0.5 mg of Chlormadinone acetate and 0.3 mg, 0.4 mg and 0.5 mg of Norethindrone. Acta Endocr., Kbh., Suppl. 144:7–46

        • Larsson-Cohn U.
        Continuous microdose norethindrone vs. combined oral contraceptives.
        in: A clinical symposium on Micronor (norethindrone 0.35 mg) continuous regimen low-dose oral contracetive. Ortho Pharmaceutica, Raritan, New Jersey1973: 4-8
        • Apelo R.
        • Veloso I.
        Clinical experience with microdose d-norgestrel as an oral contraceptive.
        Fertil.Steril. 1973; 24: 191-197
        • Board J.A.
        Contraception with norethindrone 0.35 mg administered continuously.
        Southern Medical Journal. 1976; 69: 49-52
        • Board J.A.
        Continuous norethindrone, 0.35 mg., as an oral contraceptive agent.
        Amer.J.Obstet.Gynec. 1971; 109: 531-535
        • Lawson J.P.
        • Bradshaw F.R.
        Experience with norethisterone 0.35 mg. as an oral contraceptive — a preliminary report.
        Current Medical Research and Opinion. 1972; 1: 53-61
        • Vessey M.P.
        • Mears E.
        • Andolsek L.
        • Ogrinc-Oven M.
        Randomised double-blind trial of four oral progestagen-only contraceptives.
        Lancet. 1972; 29 (April): 915-922
        • Landgren B.-M.
        • Johannisson E.
        • Masironi B.
        • Diczfalusy E.
        Pharmacokinetic and pharmacodynamic effects of small doses of nor-ethisterone released from vaginal rings continuously during 90 days.
        Contraception. 1979; 19: 253-271
        • Dickey R.P.
        Initial pill selection and managing the contraceptive pill patient.
        Int.J.Gynaecol.Obstet. 1979; 16: 547-555